|
Age
|
18–29
|
54
|
12.8
|
|
30–39
|
169
|
40.0
|
|
40–49
|
136
|
32.2
|
|
> = 50
|
64
|
15.1
|
|
Marital status
|
Single
|
97
|
22.9
|
|
Married
|
209
|
49.4
|
|
Divorced
|
81
|
19.1
|
|
Widowed
|
36
|
8.5
|
|
Gender
|
Female
|
272
|
64.3
|
|
Male
|
151
|
35.7
|
|
Resident
|
Urban
|
343
|
81.1
|
|
Rural
|
80
|
18.9
|
|
Occupation
|
Farmer
|
51
|
12.1
|
|
Merchant
|
58
|
13.7
|
|
Student
|
17
|
4
|
|
government employ
|
43
|
10.2
|
|
daily laborer
|
62
|
14.7
|
|
house life
|
101
|
23.9
|
|
Private employ
|
66
|
15.6
|
|
Other
|
25
|
5.9
|
|
Educational status
|
Illiterate
|
121
|
28.6
|
|
primary school
|
117
|
27.7
|
|
secondary school
|
142
|
33.6
|
|
Tertiary
|
43
|
10.2
|
|
Religion
|
Orthodox
|
386
|
91.3
|
|
Muslim
|
30
|
7.1
|
|
Protestant
|
7
|
1.7
|
|
Total
|
423
|
100.0
|
|
Duration of ART in year
|
<=6
|
162
|
38.3
|
|
> 6
|
261
|
61.7
|
|
Mean ART duration in year
|
7 year (+ 3)
|
423
|
100%
|
|
Base line WHO stage
|
WHO stage I
|
57
|
(13.5)
|
|
WHO stage II
|
97
|
(22.9)
|
|
WHO stage III
|
214
|
(50.6)
|
|
WHO stage IV
|
55
|
(13.0)
|
|
WHO stage during data collection
|
WHO stage I
|
11
|
(2.6)
|
|
WHO stage II
|
408
|
(96.5)
|
|
WHO stage III
|
4
|
(.9)
|
|
Type of Opportunistic infection
|
No
|
308
|
(72.8)
|
|
Protozoa
|
4
|
(.9)
|
|
Helminths
|
12
|
(2.8)
|
|
Hepatitis viruses
|
3
|
(.7)
|
|
fungal infections
|
1
|
(.2)
|
|
TB
|
89
|
(21.0)
|
|
Mixed
|
6
|
(1.4)
|
|
Initial regimen
|
D4T + 3TC + NVP
|
78
|
(18.4)
|
|
D4T + 3TC+ EFV
|
29
|
(6.9)
|
|
AZT +3TC + NVP
|
156
|
(36.9)
|
|
AZT + 3TC + EFV
|
30
|
(7.1)
|
|
TDF + 3TC + EFV
|
87
|
(20.6)
|
|
TDF + 3TC + NVP
|
31
|
(7.3)
|
|
D4T + 3TC + NVP
|
6
|
(1.4)
|
|
Pediatric 4C (AZT + 3TC + NVP)
|
6
|
(1.4)
|
|
Switching
|
No
|
261
|
(61.7)
|
|
Yes
|
162
|
(38.3)
|
|
Total
|
423
|
(100.0)
|
|
Switching
|
To 1st line drug
|
150
|
(35.5)
|
|
To 2nd line drug
|
12
|
(2.8)
|
|
Second regimen
|
AZT +3TC + NVP
|
61
|
37.7
|
|
AZT + 3TC + EFV
|
25
|
15.4
|
|
TDF + 3TC + NVP
|
25
|
15.4
|
|
TDF + 3TC + EFV
|
39
|
24.1
|
|
ABC + ddl + LPV/R
|
11
|
6.8
|
|
TDF + ddl + IPV/R
|
1
|
.6
|
|
Reason of switching drug
|
Toxicity
|
109
|
(67.3)
|
|
Pregnancy
|
7
|
(4.3)
|
|
TB
|
18
|
(11.1)
|
|
Clinical failure
|
1
|
(.6)
|
|
Age
|
9
|
(5.6)
|
|
ARV drug ADH at base line
|
Good
|
408
|
(96.5)
|
|
Fair
|
2
|
(.5)
|
|
Poor
|
13
|
(3.1)
|
|
ARV drug ADH During data collection
|
Good
|
420
|
(99.3)
|
|
Poor
|
3
|
(.7)
|
|
Base line CD4 count
|
<=199
|
267
|
(63.1)
|
|
200–349
|
120
|
(28.4)
|
|
350–499
|
27
|
(6.4)
|
|
> = 500
|
9
|
(2.1)
|
|
CD4 count during data collection
|
<=199
|
44
|
(10.4)
|
|
200–349
|
110
|
(26.0)
|
|
350–499
|
114
|
(27.0)
|
|
> = 500
|
155
|
36.6
|
|
Viral load count
|
Undetected
|
224
|
53.0
|
|
0–19
|
84
|
19.9
|
|
20–999
|
53
|
12.5
|
|
> = 1000
|
62
|
14.7
|
|
Total
|
423
|
100
|
|
Component of immunological failure
|
CD4 Falling More Than 50%
|
30
|
53.6
|
|
CD4 Falling Below Baseline
|
21
|
37.5
|
|
CD4 Persistently Below 100
|
5
|
8.9
|
|
Total
|
56
|
100
|
